Healthcare Industry News: respiratory syncytial virus
News Release - February 20, 2007
MedImmune Further Expands its Commercial Organization Expertise With Appointment of Two Additional Vice PresidentsGAITHERSBURG, Md., Feb. 20 (HSMN NewsFeed) -- MedImmune, Inc. (Nasdaq: MEDI ) today announced that it has added two senior leaders to its commercial management organization. The new executive appointments are Jamie Harrell, vice president, infectious disease marketing, and Mark Stanton, vice president, managed markets. The addition of Mr. Harrell and Mr. Stanton builds on MedImmune's commercial leadership expansion, which included several senior appointments in 2006.
"Jamie and Mark bring a depth of experience and knowledge that we expect to be critically instrumental in helping us achieve our long-term growth goals for our respiratory syncytial virus (RSV) franchise," said David M. Mott, chief executive officer and president. "They join a dedicated management team, passionate about creating value for shareholders, new medical options for patients and healthcare providers, and rewarding careers for employees."
In his new role as vice president, infectious disease marketing, Jamie Harrell is responsible for leading the strategic direction of marketing activities for SynagisŪ (palivizumab) as well as the commercialization of MedImmune's next-generation monoclonal antibody for RSV. Prior to joining MedImmune, Mr. Harrell was senior director, marketing and global market development at Centocor, Inc. In this role, he was responsible for supporting the growth of Centocor's anti-TNF monoclonal antibody in ex-U.S. markets in conjunction with Schering Plough. Mr. Harrell joined Centocor in 1999 and held positions of increasing responsibility, including senior director, marketing, rheumatology franchise, and associate director, marketing, for Centocor's cardiovascular business unit. Prior to Centocor, he held positions at Searle Pharmaceuticals and Rhone-Poulenc Rorer. Mr. Harrell holds a bachelor's degree in administration with a double major in marketing and economics from Samford University.
As MedImmune's new vice president, managed markets, Mark Stanton is leveraging his 12 years of managed care experience to build and lead MedImmune's integrated strategy to support all products in the managed care market. In his previous position at Endo Pharmaceuticals, he was the director, corporate accounts, responsible for the development of national managed market activities, including managed care organizations, pharmacy benefit management and group purchasing organizations. Prior to joining Endo, Mr. Stanton held positions of increasing responsibility at Serono, Inc., leading to director, managed care and contracting. Earlier in his career, Mr. Stanton held sales and marketing positions at the Rhone-Poulenc Group and the Boehringer Mannheim Corporation. Mr. Stanton holds a bachelor's degree in business administration from Castleton State College.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.